A prospective study to examine persistent HCV reinfection in injection drug users who have previously cleared the virus
Autor: | Hui Shen, Sue Currie, Teresa L. Wright, Daniel Tracy, James C. Ryan, Rosemary McQuaid, Michael Kim, Sally George, Alexander Monto |
---|---|
Rok vydání: | 2008 |
Předmět: |
Male
Drug medicine.medical_specialty Health Status Hepatitis C virus media_common.quotation_subject Hepacivirus Enzyme-Linked Immunosorbent Assay Toxicology medicine.disease_cause Virus Flaviviridae Recurrence Surveys and Questionnaires Internal medicine Prevalence medicine Humans Pharmacology (medical) Prospective Studies Substance Abuse Intravenous Prospective cohort study Demography media_common Pharmacology Hepatitis biology business.industry virus diseases Middle Aged medicine.disease biology.organism_classification Hepatitis C digestive system diseases Alcoholism Psychiatry and Mental health Immunology RNA Viral Female business Follow-Up Studies Psychopathology |
Zdroj: | Drug and Alcohol Dependence. 93:148-154 |
ISSN: | 0376-8716 |
Popis: | Background Many HCV-infected persons with recent or ongoing injection drug use (IDU) do not receive HCV treatment due to the perceived risk of HCV reinfection. There are few prospective studies investigating HCV reinfection among IDUs. Methods Two hundred and twenty-four persons with past or ongoing IDU were followed from 1997 to 2007. Baseline and every 6-month follow-up data were collected including demographics, IDU, and sexual behaviors. Serum was tested for the presence of HCV antibody and serially for HCV RNA. Resolvers were defined as HCV antibody and RIBA positive and RNA negative at two consecutive time points or as becoming HCV RNA negative after HCV antiviral treatment. Reinfection was defined by the presence of HCV RNA at ≥2 visits. Results One hundred and eighty-six persons had chronic HCV and 38 had resolved HCV. The resolvers were followed for a total of 214 person-years. Forty-two percent of resolvers reported ongoing IDU, representing 58 person-years of IDU. Only one reinfection occurred in the resolvers, for a reinfection rate of 0.47 cases/100 person-years of follow-up. The single reinfection, which occurred in a person who continued to inject drugs, represents a reinfection rate of 1.75 cases/100 person-years of IDU. Conclusion These data suggest that despite ongoing IDU, persistent HCV reinfection is lower than previously published. This can be attributed to a more clinically relevant definition of reinfection. This information will better help clinicians make informed decisions regarding HCV treatment options for patients who may continue to inject illicit drugs. |
Databáze: | OpenAIRE |
Externí odkaz: |